Impact Factor
3.64
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.02
1,169 total citations
h5-index
38
h5 depth signal
Cited share
77.8%
309 of 397
Total citations
1,169
Citation footprint
Metric signal
3.37
External metric anchor
Self-citation
8.2%
96 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
875
United Kingdom
265
Germany
161
Sweden
156
Netherlands
131
Citing Fields of Research
Pharmacology & Toxicology
538
Cancer Drugs
271
Statistical Methods
233
Medical Ethics
127
Oncology
124
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,880
Articles tracked across the journal lifetime
Indexed publication set
397
309 cited publications
Last 12 months
230
19.2 publications/month
Open access share
100.0%
230 OA publications in the last year
Leading citing country
United States
875 citing publications
Leading citing field
Pharmacology & Toxicology
538 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Jan. 2016-
v1, Sept. 2012-
Active Coverage
Research Focus & Classification
Indexed Subjects
Pharmacology & Toxicology
Statistical Methods
Cancer Drugs
Immunology
Drug Delivery Systems
AI & Machine Learning
Issuing & Sponsoring Bodies
Contributor
American Society for Clinical Pharmacology and Therapeutics
Broad Categories
Pharmacology
Pharmacology & Toxicology
Statistical Methods
Medical Ethics
Cancer Drugs
Cardiology
Hematology
Immunology
MeSH Descriptors
Pharmacokinetics
Pharmacological Phenomena
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
The target‐engagement predictor, implemented within the InSilicoTrials cloud‐based, AI‐powered platform for model‐informed drug discovery and development, enables early exploration of time‐dependent pharmacological responses. Predictions...
02
DOI 10.1002/psp4.70349
Open DOI
Longitudinal Modeling of Cardiometabolic Dysfunction in Patients With Type 2 Diabetes Using Item Response Theory
Cardiometabolic dysfunction in patients with type 2 diabetes (T2D) is reflected by multiple risk factors and cannot be fully characterized by any single biomarker. Item response theory (IRT) provides a framework for integrating observed ...
03
DOI 10.1002/psp4.70350
Open DOI
Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration”
04
DOI 10.1002/psp4.70271
Open DOI
Issue Information
05
DOI 10.1002/psp4.70348
Open DOI
Preclinical Pharmacokinetic‐Pharmacodynamic Modeling of Antibody Nanoconjugates for Breast Cancer Treatment
Over the past 5 years, the number of antibody–drug conjugates (ADCs) entering the oncology market has surged. By contrast, the clinical use of immunoliposomes—nanoparticles that also employ antibodies as targeting agents (i.e., antibody–...
06
DOI 10.1002/psp4.70346
Open DOI
Causal Exposure‐Response Analysis: Estimands, Time‐Varying Confounding, and the Parametric g‐Formula
Exposure‐response (ER) analysis often informs dose selection in clinical drug development, but the underlying causal assumptions are rarely made explicit. Exposure metrics commonly used in practice can have limitations: time‐to‐event met...
07
DOI 10.1002/psp4.70352
Open DOI
Integrating a Tumor Size‐Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody‐Drug Conjugates in Non‐Small Cell Lung Cancer
Antibody‐drug conjugate (ADC) development in solid tumors faces efficacy and safety challenges from heterogeneous target expression, limited tumor penetration, and off‐target payload exposure. We developed a spatial quantitative systems ...
08
DOI 10.1002/psp4.70330
Open DOI
Dynamic Prediction of Clinical Endpoints in Survival Analysis With Machine and Deep Learning: A Systematic Review and Regulatory Perspective
Accurate prediction of time‐to‐event outcomes is essential for clinical decision‐making and model‐informed drug development (MIDD). Conventional survival models may inadequately represent complex longitudinal patient trajectories, time‐d...
09
DOI 10.1002/psp4.70351
Open DOI
Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration
10
DOI 10.1002/psp4.70347
Open DOI
Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs
Tuberculosis (TB) treatment requires long‐term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open‐source, modular framework connecting high‐throughput PBPK...